Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6190305 | Cancer Treatment Communications | 2015 | 4 Pages |
Abstract
New areas of research continue to examine the role of non-androgen receptor pathways in prostate cancer treatment. The phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (mTOR) pathway may be a target for prostate cancer therapy. Somatostatin receptor signaling inhibits intracellular PI3K/Akt signaling, making it an attractive target for combination therapy. We conducted a phase II open label clinical trial examining the use of somatostatin receptor agonist, pasireotide (SOM230) in combination with mTOR inhibitor, everolimus in metastatic castrate-resistant chemotherapy-naïve prostate cancer patients. Of the 6 patients enrolled in the study, only 1 patient had >50% PSA reduction from baseline. Three patients withdrew due to grade 3 adverse events. The study was closed early due to toxicity profiles and no further development was planned for this combination treatment in prostate cancer.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Jianqing Lin, Aileen Deng, Jean Hoffman-Censits, Geoffrey Gibney, Terry Hyslop, Brooke Miller, Deborah Kilpatrick, Serge Jabbour, William Kevin Kelly,